Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx Group (MDXG) EBITDA: 2011-2024

Historic EBITDA for Mimedx Group (MDXG) over the last 14 years, with Dec 2024 value amounting to $58.9 million.

  • Mimedx Group's EBITDA rose 98.80% to $22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.9 million, marking a year-over-year decrease of 14.91%. This contributed to the annual value of $58.9 million for FY2024, which is 58.60% up from last year.
  • As of FY2024, Mimedx Group's EBITDA stood at $58.9 million, which was up 58.60% from $37.1 million recorded in FY2023.
  • Over the past 5 years, Mimedx Group's EBITDA peaked at $58.9 million during FY2024, and registered a low of -$45.4 million during FY2020.
  • Moreover, its 3-year median value for EBITDA was $37.1 million (2023), whereas its average is $27.1 million.
  • Per our database at Business Quant, Mimedx Group's EBITDA tumbled by 114.55% in 2020 and then spiked by 352.03% in 2023.
  • Over the past 5 years, Mimedx Group's EBITDA (Yearly) stood at -$45.4 million in 2020, then surged by 84.47% to -$7.1 million in 2021, then plummeted by 108.86% to -$14.7 million in 2022, then skyrocketed by 352.03% to $37.1 million in 2023, then skyrocketed by 58.60% to $58.9 million in 2024.